Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.40 |
| ▸ | RAB9A | P51151 | 7/20 | 0.40 |
| ▸ | MEN1 | O00255 | 6/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | OTUD7B | Q6GQQ9 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.38 |
| ▸ | MAT2A | P31153 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | KDR | P35968 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | INSR | P06213 | 1/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7636715 | 1.00 | NPC1 (0.40) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL7658598 | 0.93 | NPC1 (0.38) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL7658600 | 0.93 | NPC1 (0.38) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL7631160 | 0.77 | NPC1 (0.44) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL7631165 | 0.77 | NPC1 (0.44) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL7630182 | 0.75 | MAPT (0.44) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL7630186 | 0.75 | MAPT (0.44) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4259969 | 0.75 | MAPT (0.44) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL12257145 | 0.71 | NPC1 (0.46) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3793730 | 0.68 | NPC1 (0.47) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6365609-B1 | MODULATORS FOR ATP-REGULATED POTASSIUM CHANNELS; TREATING DIABETES OR HYPERINSULINEMIA | NOVO NORDISK A/S (DK) | 2002-04-02 | — | — | US | claimed |
| US-6362205-B2 | FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR SYSTEM DISORDERS, PULMONARY SYSTEM DISORDERS, GASTROINTESTINAL SYSTEM DISORDERS, AND ENDOCRINOLOGIC SYSTEM DISORDERS | NOVO NORDISK A/S (DK) | 2002-03-26 | — | — | US | claimed |
| US-20010025111-A1 | Substituted 3,3-diamino-2-propenenitriles, their preparation and use | HANSEN JOHN BONDO (DK) | 2001-09-27 | — | — | US | claimed |
| US-6365609-B1 | MODULATORS FOR ATP-REGULATED POTASSIUM CHANNELS; TREATING DIABETES OR HYPERINSULINEMIA | NOVO NORDISK A/S (DK) | 2002-04-02 | — | — | US | disclosed |
| US-6362205-B2 | FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR SYSTEM DISORDERS, PULMONARY SYSTEM DISORDERS, GASTROINTESTINAL SYSTEM DISORDERS, AND ENDOCRINOLOGIC SYSTEM DISORDERS | NOVO NORDISK A/S (DK) | 2002-03-26 | — | — | US | disclosed |
| US-20010056188-A1 | Substituted 3,3-diamino-2-propenenitriles, their preparation and use | HANSEN JOHN BONDO (DK) | 2001-12-27 | — | — | US | disclosed |
| US-20010025111-A1 | Substituted 3,3-diamino-2-propenenitriles, their preparation and use | HANSEN JOHN BONDO (DK) | 2001-09-27 | — | — | US | disclosed |
| EP-1124794-A1 | SUBSTITUTED 3,3-DIAMINO-2-PROPENENITRILES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2001-08-22 | — | — | EP | disclosed |
| WO-2000027805-A1 | SUBSTITUTED 3,3-DIAMINO-2-PROPENENITRILES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010056188-A1 | Substituted 3,3-diamino-2-propenenitriles, their preparation and use | TNNI3, PCCA, NPR3 | NPC1 3348/4885RAB9A 3761/4885MEN1 212/4885 |
| US-20010025111-A1 | Substituted 3,3-diamino-2-propenenitriles, their preparation and use | NPR3, NPR1, PKD1 | NPC1 2952/4885RAB9A 3077/4885MEN1 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.